Show simple item record

AuthorRoberts, Matthew J.
AuthorRichards, Renee S.
AuthorChow, Clement W.K.
AuthorDoi, Suhail A.R.
AuthorSchirra, Horst Joachim
AuthorBuck, Marion
AuthorSamaratunga, Hemamali
AuthorPerry-Keene, Joanna
AuthorPayton, Diane
AuthorYaxley, John
AuthorLavin, Martin F.
AuthorGardiner, Robert A.
Available date2016-10-12T10:45:31Z
Publication Date2016-09
Publication NameProstate Internationalen_US
Identifierhttp://dx.doi.org/10.1016/j.prnil.2016.04.002
CitationRoberts MJ, Richards RS, Chow CWK, et al. Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers. Prostate International. 2016;4(3):97-102
ISSN22878882
URIhttp://www.sciencedirect.com/science/article/pii/S2287888216300022
URIhttp://hdl.handle.net/10576/4877
AbstractBackground Prostate cancer (PCa) diagnosis requires improvement with the aid of more accurate biomarkers. Postejaculate urethral washings (PEUW) could be a physiological equivalent to urine obtained following rectal prostatic massage, the current basis for the prostate cancer antigen 3 (PCA3) test. The aim of this study was to investigate if PEUW contained prostate-based material, evidenced by the presence of prostate specific antigen (PSA), and to evaluate the diagnostic performance of PEUW-based biomarkers. Methods Male patients referred for elevated serum PSA or abnormal digital rectal examination provided ejaculate and PEUW samples. PSA, PCA3, and β2-microglobulin (β2M) were quantified in ejaculate and PEUW and compared with absolute and clinically significant (according to D’Amico criteria) PCa presence, as determined by biopsies. Diagnostic performance was determined and compared with serum PSA using receiver operating characteristic analysis. Results From 83 patients who provided PEUW samples, paired analysis with ejaculate samples was possible for 38 patients, while analysis in an unpaired, extended cohort was possible for 62 patients. PSA and PCA3 were detected in PEUW, normalized to β2M, and PCA3:PSA was calculated. In predicting absolute PCa status, PCA3:β2M in ejaculate [area under the curve (AUC) 0.717] and PEUW (AUC 0.569) were insignificantly better than PCA3:PSA (AUC 0.668 and 0.431, respectively) and comparable with serum PSA (AUC 0.617) with similar trends observed for the extended cohort. When considering clinically significant PCa presence, serum PSA in the comparison (AUC 0.640) and extended cohorts (AUC 0.665) was comparable with PCA3: β2M (AUC 0.667) and PCA3:PSA (AUC 0.605) in ejaculate, with lower estimates for PEUW in the comparison (PCA3: β2M AUC 0.496; PCA3:PSA AUC 0.342) and extended (PCA3: β2M AUC 0.497; PCA3:PSA AUC 0.469) cohorts. The statistical analysis was limited by sample size. Conclusion PEUW contains prostatic material, but has limited diagnostic accuracy when considering cell-derived DNA analysis. PCA3-based markers in ejaculate are comparable to serum PSA and digital rectal examination–urine markers.
SponsorRoyal Brisbane and Women's Hospital Foundation (Ref: 2014002678), the Prostate Cancer Foundation of Australia and Cancer Council Queensland
Languageen
PublisherElsevier
SubjectBiomarker
SubjectEjaculate
SubjectmRNA
SubjectProstate Cancer
SubjectProstate Cancer Antigen 3
SubjectProstate Specific Antigen
TitleProstate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers
TypeArticle
Pagination97-102
Issue Number3
Volume Number4
Open Access user License http://creativecommons.org/licenses/by-nc-nd/4.0/


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record